After training in medicine and neurology in London, Tanzania, and Southampton Nigel Leigh was appointed to the University Chair of Neurology at King’s in 1989. There he established a research program in MND (ALS) to understand the causes, consequences, and treatment of MND and other neurodegenerative disorders. The King’s MND Care and Research Centre was formally inaugurated in 1995 as a model for multi-disciplinary care and research worldwide. In 1998 he won The Forbes Norris Award of the International Alliance of MND/ALS Associations, and in 2003 he was awarded the Erb-Duchenne Prize of the German Neuromuscular Society, and in 2004 was awarded the Sheila Essey Prize for ALS Research from the American Academy of Neurology. He is a Fellow of the Academy of Medical Sciences, and corresponding Fellow of the American Academy of Neurology and the American Neurological Association. He is now Professor of Neurology at Brighton and Sussex Medical School, Brighton UK and Honorary Consultant Neurologist at Brighton and Sussex University Hospitals Trust. His research continues to focus on the causes, mechanisms, and treatment of MND and related neurodegenerative disorders. He co-leads MIROCALS- Modifying Immune Responses and Outcomes in ALS, a clinical trial of low dose interleukin-2 incorporating extensive biomarker studies, funded through the European Union Horizon 2020 programme, in partnership with the MND Association. He is Director of the Sussex MND Care and Research Network. He continues his links and collaborations with King’s as Emeritus Professor of Neurology.